Aclaris Therapeutics - 9 Asse im Ärmel!

und endlich einmal shorter barbeque!

After hours: 1.99 +0.31 (18.45%)

finance.yahoo.com/quote/ACRS?p=ACRS

( 22M americans affect each year = MEGA MARKET POTENTIAL
"If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts"
"They affect an estimated 19 million Americans each year with a higher incidence in children than adults." )

www.globenewswire.com/news-release/2019/...-of-Common-Wa.html

Das könnte schlecht für shortis ausgehen..

www.nasdaq.com/market-activity/stocks/acrs/short-interest

SETTLEMENT DATE	SHORT INTEREST	AVG. DAILY SHARE VOLUME	DAYS TO COVER
10/15/2019	4,259,215	1,729,232	2.463067

(positive) Phase3  A-101 Studiendaten

investor.aclaristx.com/news-releases/...on-meets-primary-and-1

finance.yahoo.com/chart/ACRS/...pdCI6Im1pbnV0ZSJ9fX1dfQ%3D%3D

fintel.io/ss/us/acrs

hier große Investoren wie der israelische Milliardär oder der Fonds der Uni aus USA hier eingestiegen sind? Da muss noch etwas mehr sein als nur die Warzen. Die Ergebniss der rheumatoiden Athritis Ende diesen Jahres wird interessant sein. Die anderen Sachen sind noch sehr früh in der Entwicklung.

seekingalpha.com/news/...utics-eps-misses-0_65-misses-revenue

old.nasdaq.com/de/symbol/acrs/real-time

Dieser Markt wächst allmählich mit einer konstanten CAGR von 3,8% im Prognosezeitraum 2019-2026. Hier sind nur wenige Namen der führenden Unternehmen aufgeführt - Foamix Pharmaceuticals Ltd., Allergan, Bausch Health, Sol-Gel Technologies Ltd., Bayer AG , Nestlé, PRUGEN, Merck & Co., Inc., AbbVie Inc., Unilever, Croda International, Colorescience, Inc., Perrigo, Aclaris Therapeutics, Inc., Lupine Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc, Dr Reddy's Laboratories Ltd., unter anderem Mylan NV.

Rosacea Treatment Market Growth Powered With Latest Development Scenario and Influencing Trends...

heraldcorrespondent.com/...chnologies-ltd-bayer-ag-nestle.html

SK auf TH :)

Mein Tipp einfach komplett lesen.. Sehr Positiv..

Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT

Thomson Reuters StreetEvents•November 9, 2019

https://finance.yahoo.com/news/edited-transcript-acrs-earnings-conference-193824891.html

Spring Forward With Aclaris Therapeutics, Inc. (ACRS)

By Nicola Day

November 8, 2019

--------------------------------------------------

Most of the analysts surveyed by Thomson/First Call think quite highly of Aclaris Therapeutics, Inc. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $9 on shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), which corresponds to 383.87% upside potential than its current market price of $1.86 and implies potential despite the recent advance in the price. However, their current target price has fallen from $17.33 a month ago and is down handily from the consensus target of $17.33 a quarter ago.

https://pressrecorder.com/2019/11/08/spring-forward-with-aclaris-therapeutics-inc-acrs-2/

eingedeckt :-)

Aber viel potenzial..

Drug discovery

Exploring the kinome to unlock new possibilities

With our sights set on discovery, Aclaris is currently exploring the kinome, a subset of the human genome that consists of a collection of approximately 518 protein kinases, one of the largest of all human gene families, and a key control point in cell behavior.

Classified into eight major groups based on their structural similarity to each other, kinases are key regulators of cell function for many cell processes. By transferring phosphates to other molecules, kinases can induce a cellular response to environmental cues. Dysregulation and/or mutations in kinases can disrupt normal cell signaling and lead to diseases ranging from diabetes to cancer, making them important targets for drug development.

Currently, there are a number of approved kinase inhibitors on the market, such as Xeljanz® (tofacitinib citrate), Gleevec® (imatinib mesylate), and Tarceva® (erlotinib). However, these drugs only target a small fraction of the kinome, with many clinically relevant kinases lacking validated inhibitors.

We’re focused on the design and development of kinase inhibitors that target key enzymes involved in chronic inflammation, autoimmune disease, or the regulation of cancer growth, survival and metastasis.

https://www.aclaristx.com/drugdiscovery/

Kinase inhibitors in focus after Merck bid for ArQule

Dec. 9, 2019 10:40 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor

Merck's $2.7B bid for ArQule is yet another example of Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK).

https://seekingalpha.com/news/3524810-kinase-inhibitors-in-focus-after-merck-bid-for-arqule

bei der Pipeline kann auch mal das schnell passieren, was bei Xbit aktuell passiert ist!

Mache ich hier nicht wieder. News kommen oft Afterhour.
Die sind voll mit Cash und schmaler Freefloat.
Ich habe daraus gelernt, mache nicht jeden kleinen Hüpfer mit und bleibe über Nacht auf jeden Fall "drin"..

Die Frage ist, wann knacken wir diese Marke? Dieses Jahr noch?

flashalert.me/...of-Vincent-Milano-to-Board-of-Directors.html

newsfilter.io/a/241fd27aec8e8e504669b40f537236e8

...und das wegen einer Phase 1, das zeigt doch wie viel Potential hier drin steckt bei dem Portfolio. Wenn wir mal morgen über 2 USD bleiben könnte es endlich mal langsam aufwärts gehen www.globenewswire.com/news-release/2020/...MK2-Inhibitor.html

positive Phase1 Studiendaten bei ATI-450

investor.aclaristx.com/news-releases/...results-phase-1-single

..die 1,xx $ sehen wir nie wieder!!